7 Juillet – 17h – CEST
Outsourcing drug discovery has become a widely accepted approach in the pharmaceutical industry, from virtual biotechnology to large pharmaceutical companies, as part of the globalization process. This represents a cost-effective opportunity to access specialized technologies and expert scientific resources with extensive knowledge of pharmaceutical drug discovery development. Oncodesign’s goal with the DRIVE™ offering is to provide its customers with the best possible options and cutting-edge technologies to advance their drug discovery in the shortest possible time with the highest quality.
Oncodesign does this by setting up, under a single management, privileged partnerships with selected and trusted companies sharing the same values of innovation and quality as its own.
Research and validation of results are important phases in early drug discovery. With Program, Oncodesign provides DNA-encoded libraries, fragment screening as well as Hit validation using NanoDSF, MST, SPR, ITC and structural biology (Cryo-EM and X-ray crystallography) supported by the ‘artificial intelligence.
Key learning objectives
- Introduction to a solution provider from hits finding to IND filing
- Advantages of drug discovery integrated provider vs silos approach
- Special focus on Hit identification and validation across DNA encoded libraries, Artificial Intelligence, Biophysics and Biostructures